CSL Limited (ASX:CSL) has cut FY26 guidance and flagged US$5 billion in non-cash impairments including CSL Vifor, as the interim CEO resets the story.
Healthcare Stocks
Amplia (ASX:ATX) Adds Ovarian Trial with ANZGOG After Narmafotinib Hits 35% Pancreatic Response Rate
Amplia Adds Ovarian Trial After Pancreatic Success
Amplia Therapeutics (ASX:ATX) has opened a new chapter in its drug story. On 8 May, the small-cap biotech announced a partnership with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to test its lead drug, narmafotinib, in ovarian cancer. The new study, called PRROSE, will treat patients with…
ASX Healthcare Stocks Caught in the GLP-1 Storm After Eli Lilly's Blockbuster Quarter
Eli Lilly (NYSE:LLY) just delivered a knockout first-quarter 2026 result on Thursday, with sales of its weight-loss drug Mounjaro more than doubling and shares jumping 6% on the day. For ASX investors who still think the GLP-1 weight-loss boom is only a…
ImpediMed (ASX:IPD) raised A$15.2m and cut costs as it works toward FY28 operating cash flow breakeven through SOZO growth.
For investors who missed the run in Novo Nordisk shares, Eli Lilly (NYSE:LLY) appeared to be the next best thing. And perhaps those who bought into Eli Lilly would have less regrets with Novo Nordisk shares having shed over 70% since their all time high in June 2024. and Eli Lilly shares gone relatively well…
a2 Milk Company (ASX:A2M) recalled 63,078 tins of US label infant formula, but the direct financial impact looks contained.
For every one of the ASX Biotech Success Stories, there are several failures. While a handful of companies can and do convert clinical data into extraordinary value, many others run into the barrier that decides everything: the primary endpoint.
The successes tend to follow a recognisable pattern — a credible clinical signal, external validation, and either…
ResMed (ASX:RMD) just delivered what looked like a great quarter. Revenue jumped 11%, earnings climbed 21%, and the company beat analyst expectations. On paper, this should have been a green day for the share price. Instead, RMD shares dropped on Friday and ended the week lower.
So what's going on? When a company posts strong numbers,…
LTR Pharma (ASX:LTP) reported 10 minute SPONTAN Tmax data with no serious safety events, strengthening its planned FDA pathway.
Beats revenue ceiling, EBITDA nearly doubles guidance midpoint as Myriad carries the result
The number that matters in Aroa Biosurgery's (ASX:ARX) FY26 preliminary result is not the revenue beat itself. It is the gap.
Aroa guided to NZ$92 to NZ$100 million in revenue at constant currency and printed NZ$101 million on that basis, exceeding the…
